Reverb Therapeutics Debuts Its Amplifier™ Platform for Redirecting Endogenous Cytokines
Reverb Therapeutics, a leader in the emerging paradigm of redirecting endogenous cytokines as treatments for life-threatening diseases, debuts with seed financing led by founding investor Amplitude Ventures and participation from the Multiple Myeloma Research Foundation’s venture philanthropy arm, the Myeloma Investment Fund .
- Reverb Therapeutics, a leader in the emerging paradigm of redirecting endogenous cytokines as treatments for life-threatening diseases, debuts with seed financing led by founding investor Amplitude Ventures and participation from the Multiple Myeloma Research Foundation’s venture philanthropy arm, the Myeloma Investment Fund .
- Reverb Therapeutics is advancing its novel antibody-based AmplifierTM platform to treat a broad range of diseases with endogenous cytokines that naturally occur within the body.
- Instead of using heavily engineered exogenous cytokines to treat disease—which have consistently presented challenges such as systemic toxicity, immunogenicity and challenging production requirements—Reverb’s antibodies redirect endogenous, natural cytokines to cells of interest.
- “We are keenly aware of the clinical obstacles to more widespread use of exogenous cytokines to treat patients,” said David de Graaf, Ph.D., Co-founder and CEO of Reverb Therapeutics.